cyclic peptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-10-28. Where a claim depends on a specific study, the study is described rather than over-claimed.
How receptor activation translates into a change in desire is not established in detail. Proposed steps include modulation of dopaminergic signalling in reward circuits and downstream effects on autonomic tone. Human data consist mainly of clinical trials measuring self-reported outcomes rather than direct measurements of brain activity or transmitter release. The transient rise in blood pressure sometimes observed after administration is likewise reported consistently but explained only partly by known melanocortin pathways.
Melanocortin receptors form a family of five G-protein-coupled proteins, labelled MC1R through MC5R, that respond to peptides derived from pro-opiomelanocortin. Alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone are the best-known endogenous ligands. The receptors are distributed differently across tissues, so a single agonist can produce effects in the brain, skin, adrenal gland and vasculature. This distribution explains why one peptide can influence both pigmentation and motivated behaviour.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
| Property | Value | Notes |
|---|---|---|
| Primary receptor target | MC4R agonist | Subtype most often linked to behavioural effects |
| Other reported targets | MC1R, MC3R, MC5R | Activity is not selective for a single subtype |
| Endogenous ligand class | Melanocortin peptides | Alpha-MSH and ACTH act on the same family |
| Peptide architecture | Cyclic heptapeptide | Lactam bridge between the aspartate and lysine residues |
| Central action | Inferred from animal models | Not directly measured in the human brain |
After subcutaneous dosing, peak plasma concentrations appear within roughly one hour, and elimination is fast, with a half-life on the order of a few hours. Degradation is mainly proteolytic, and at least one circulating fragment retains receptor activity, so parent-drug levels alone do not describe total exposure. Clearance does not depend heavily on hepatic cytochrome enzymes, which lowers the likelihood of common metabolic interaction routes. Data in renal or hepatic impairment are limited. Repeated dosing does not appear to produce marked accumulation given the short half-life.
Reported pharmacodynamic effects include transient rises in blood pressure and heart rate, flushing, nausea and headache, appearing soon after dosing and resolving within hours. These responses were dose-related in early studies and shaped the label's cardiovascular cautions and blood pressure monitoring advice. Gastrointestinal upset is the most frequent reason cited for discontinuation in trials. Whether the vascular signal attenuates with repeated use is not settled. Central effects on desire are described as emerging over weeks rather than immediately, which points to a cumulative rather than acute process.
The compound binds several melanocortin receptor subtypes rather than a single target, with the strongest functional activity reported at MC4R and measurable activity at MC1R, MC3R and MC5R. MC4R populations are dense in hypothalamic nuclei that integrate energy balance, autonomic tone and reproductive behaviour, which is the anatomical basis for the proposed pro-desire effect. Because binding is not subtype-selective, pigmentary and vascular effects accompany central activity. Improving subtype selectivity is an active area of analogue design. Direct causal mapping from receptor occupancy to reported desire change in humans is not fully established.
Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
Activation of MC4R in the hypothalamus is thought to influence dopaminergic signaling, which in turn affects arousal and desire. This mechanism differs from that of phosphodiesterase type 5 inhibitors, which act primarily on vascular smooth muscle in the genital region. Because the pathway is central rather than peripheral, effects are not strictly dependent on local blood flow. The precise downstream cascade linking receptor binding to behavioral outcomes remains an area of ongoing investigation.
Clinical development of bremelanotide proceeded through several reformulation attempts. An early intranasal version was discontinued, and a subcutaneous auto-injector formulation later received approval for hypoactive sexual desire disorder in premenopausal women. Approval decisions have varied by country and over time, and the product has not been universally adopted. Blood pressure elevation is a documented effect, which is why some jurisdictions require monitoring after administration. The clinical evidence base continues to evolve as additional studies are published.
The melanocortin system comprises five G protein-coupled receptors, designated MC1 through MC5, that signal mainly through cyclic AMP accumulation. MC1R and MC2R are associated with pigmentation and adrenal steroid production, while MC3R and MC4R are expressed in the central nervous system and influence energy balance and behavior. MC5R appears in exocrine tissues. Natural agonists include alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone, and endogenous antagonists such as agouti-related protein modulate the same sites. This receptor family provides the framework within which bremelanotide activity is described.
Bremelanotide acts as an agonist at several melanocortin receptors, with the strongest reported activity at MC4R and measurable activity at MC1R and MC3R. Because MC4R is expressed in hypothalamic and limbic circuits, the proposed mechanism links receptor activation to modulation of central pathways involved in desire rather than to direct effects on peripheral genital tissue. The precise downstream steps remain incompletely characterized, and evidence for the involvement of specific neurotransmitters is suggestive rather than settled. Nausea and blood pressure elevation reported during trials are consistent with melanocortin signaling outside the intended target circuit.
=== In LTP === When alpha-CaMKII is knocked out in mice, LTP is reduced by 50%. This can be explained by the fact that beta-CaMKII is responsible for approximately 65% of CaMKII activity. LTP can be completely blocked if CaMKII is modified so that it cannot remain active. After LTP induction, CaMKII moves to the postsynaptic density (PSD). However, if the stimulation does not induce LTP, the translocation is quickly reversible. Binding to the PSD changes CaMKII so that it is less likely to become dephosphorylated. CaMKII transforms from a substrate for Protein Phosphatase 2A (PP2A), which is responsible for dephosphorylating CaMKII, to that of Protein Phosphatase 1. Strack, S. (1997) demonstrated this phenomenon by chemically stimulating hippocampal slices. This experiment illustrates that CaMKII contributes to the enhancement of synaptic strength. Sanhueza et al. found that persistent activation of CaMKII is necessary for the maintenance of LTP. She induced LTP in hippocampal slices and experimentally applied an antagonist (CaMKIINtide) to prevent CaMKII from remaining active. The slices that were applied with CaMKIINtide showed a decrease in Normalized EPSP slope after the drug infusion, meaning that the induced LTP reversed itself. The Normalized EPSP slope remained constant in the control; CaMKII continues to be involved in the LTP maintenance process even after LTP establishment. CaMKII is activated by calcium/calmodulin, but it is maintained by autophosphorylation. CaMKII is activated by the NMDA-receptor-mediated Calcium elevation that occurs during LTP induction.
== White LEDs == There are two primary ways of producing white light-emitting diodes (WLED). One is to use individual LEDs that emit three primary colors—red, green and blue—and then mix all the colors to form white light. The other, more common method is to use a phosphor material to convert monochromatic light from a blue or UV LED to broad-spectrum white light, similar to a fluorescent lamp. The yellow phosphor is made of cerium-doped YAG crystals suspended in the package or coated on the LED. This YAG phosphor causes white LEDs to appear yellow when off, and the spaces between the crystals allow some blue light to pass through in LEDs with partial phosphor conversion. Alternatively, white LEDs may use other phosphors like manganese(IV)-doped potassium fluorosilicate (PFS). PFS assists in red light generation, and is used in conjunction with a conventional Ce:YAG phosphor. In LEDs with PFS phosphor, some blue light passes through the phosphors, the Ce:YAG phosphor converts blue light to green and red (yellow) light, and the PFS phosphor converts blue light to red light. The color emission spectrum or color temperature of white phosphor-converted and other phosphor-converted LEDs can be controlled by changing the concentration of several phosphors that form a phosphor blend used in an LED package. The 'whiteness' of the light produced is engineered to suit the human eye. Because of metamerism, it is possible to have quite different spectra that appear white. The appearance of objects illuminated by that light may vary as the spectrum varies.
== # == 2-amino-4-deoxychorismate dehydrogenase - 2-dehydropantolactone reductase (B-specific) - 2-methylacyl-CoA dehydrogenase - 2-nitropropane dioxygenase - 2-oxobutyrate synthase - (2,3-dihydroxybenzoyl)adenylate synthase - 2,4-Dihydroxy-1,4-benzoxazin-3-one-glucoside dioxygenase - 2010107G12Rik - 27-hydroxycholesterol 7alpha-monooxygenase - 3' end - 3' flanking region - 3-hydroxy-2-methylpyridinecarboxylate dioxygenase - 3-Ketosteroid 9alpha-monooxygenase - 3-oxoacyl-(acyl-carrier-protein) reductase (NADH) - (3,5-dihydroxyphenyl)acetyl-CoA 1,2-dioxygenase - 3(or 17)a-hydroxysteroid dehydrogenase - 3110001I22Rik - 3alpha-hydroxyglycyrrhetinate dehydrogenase - 4932414N04Rik - 3alpha-hydroxysteroid dehydrogenase (A-specific) - 3alpha,7alpha,12alpha-trihydroxy-5beta-cholestanoyl-CoA 24-hydroxylase - 3alpha,7alpha,12alpha-trihydroxycholestan-26-al 26-oxidoreductase - 4-Cresol dehydrogenase (hydroxylating) - 4-Hydroxycyclohexanecarboxylate dehydrogenase - 4-hydroxyphenylacetaldehyde oxime monooxygenase - 4-hydroxyphenylpyruvate oxidase - 4-Nitrophenol 4-monooxygenase - 4933425L06Rik - 5' end - 5' flanking region - 5-pyridoxate dioxygenase - 6-endo-hydroxycineole dehydrogenase - 7-deoxyloganin 7-hydroxylase - 7beta-hydroxysteroid dehydrogenase (NADP+) - 8-oxocoformycin reductase - 12beta-hydroxysteroid dehydrogenase - 25-hydroxycholesterol 7α-hydroxylase -
=== Early work === Following the completion of his formal education, Stein became a researcher under Bergmann at Rockefeller Institute, where much of his most important work was done. Stanford Moore joined Bergmann's lab in 1939, where he and Stein began research focusing on amino acids. According to Moore, "During the early years of our cooperation, Stein and I worked out a system of collaboration that lasted for a lifetime." Their work in this area was disrupted with the beginning of World War II, and they temporarily parted ways to aid the war efforts, Stein staying with Bergmann to research the molecular scale effect of blister agents on the human body. They began collaborating again, however, after Bergmann died in 1944 and they were given an opportunity by the Director of the Rockefeller Institute, Herbert S. Gasser, to continue Bergmann's work in amino acids.
Recommendations are to include multiple types of exercise in exercise programs, and to prescribe exercise as early as possible in addition to medication, to gain the benefits of regular, long-term activity. Aerobic and resistance training exercise guidelines for Parkinson disease recommend 3–5 days per week of aerobic training (doing 20–60 minutes at moderate intensity) and 2–3 days per week of resistance training (doing 1-3 sets, of 8-12 repetitions, at between 40%-50% of the maximum for 1 repetition). Exercise is generally considered safe, with studies in PD reporting no serious adverse events and a very low risk of other events such as soreness, joint inflammation, fatigue, dizziness, or falls. Drop-out rates were comparable for exercising and non-exercising controls, with a generally high rate of exercise adherence.
Sources: en.wikipedia.org
== Education and career == In 1987, Viswanathan completed his MBBS degree from Govt. Stanley Medical College. He later went on to pursue his MD in Internal Medicine at the Kasturba Medical College, Mangalore, which he completed in 1991. In 1999, Viswanathan earned his Ph.D. in Diabetic Nephropathy from The Tamil Nadu Dr. M.G.R. Medical University (TNMGRMU). Additionally, he has advanced post-graduate training in diabetes. In 2010, Viswanathan completed his FRCP from the Royal College of Physicians in London. He serves as the President of Prof. M. Viswanathan Diabetes Research Centre, a WHO Collaborating centre for Research, Education and Training, and a Scientific & Industrial Research Organization (SIRO) recognized by the Department of Scientific and Industrial Research (Govt. of India). In 2019, he was the National Vice President of the Research Society for the Study of Diabetes (RSSDI). Viswanathan is a member of the European Association for the Study of Diabetes (EASD), the European Association for Study of Diabetes (EASD) as well as the European Diabetic Nephropathy Study Group (EDNSG). Additionally, he is a founding member of the Diabetic Foot Study Group (DFSG). Viswanathan was involved in drafting guidelines for wound healing and offloading as part of The International Working Group on the Diabetic Foot (IWGDF) will release these guidelines next year, which are updated every four years. Viswanathan has previously drafted infection guidelines in 2015 and recommendations for footwear for diabetic foot ulcers in 2019.
Side-door vessels have water-tight ports on the ship's hull, which open into a cargo hold. Elevators or ramps leading from the quay serve as loading and discharging access for the forklifts or conveyors. Inside these access ports or side doors, pallet lifts or another series of conveyors bring the cargo to the respective decks. This special design makes the vessels particularly well suited for inclement weather operations as the tops of the cargo holds are always closed against rain and sun. Conventional vessels have a traditional cargo operation with top opening hatches and cranes/derricks. On such ships, when facing wet weather, the hatches need to be closed to prevent heavy rain from flooding the holds. Both above ship types are well suited for the handling of palletized and loose cargo. Refrigerated container ships are specifically designed to carry containerised unit loads where each container has its individual refrigerated unit. These containers are nearly always twenty-foot equivalent units (often called TEU) that are the size of "standard" cargo containers that are loaded and unloaded at container terminals and aboard container ships. These ships differ from conventional container ships in their design, power generation, and electrical distribution equipment. They need provisions made for powering each container's cooling system. Because of their ease of loading and unloading cargo many container ships are now being built or redesigned to carry refrigerated containers.
=== Human trafficking === Human trafficking is a modern form of slavery where people are forced, tricked, or pressured into working or doing sexual acts. It can happen anywhere and affect anyone, no matter their age, race, or background.
=== Selected books === Diagnosis and Management of Renal Disease and Hypertension (1988) ISBN 9780812111293 Immunohistology in Diagnostic Pathology (1989) ISBN 9780849349874 Non-neoplastic Kidney Diseases (2005) ISBN 9781881041962 Primer on Kidney Diseases (2009) ISBN 9781416051855 Fundamentals of Renal Pathology (2013) ISBN 9783642390791 Heptinstall's Pathology of the Kidney (2024) ISBN 9781975161538
Sources: en.wikipedia.org
Bremelanotide binds several melanocortin receptors, and MC4R is the subtype most often cited as responsible for its behavioural effects. Activity at MC1R, MC3R and MC5R is also reported. Selectivity is therefore described as limited rather than precise.
It is not classified as a vasodilator, and its proposed site of action is the central nervous system rather than peripheral vessels. Some trial participants show small transient blood pressure changes. Whether those changes arise centrally or through another route remains an open question.
Most evidence comes from animal models and from indirect human outcomes such as self-reported desire. Direct measurements of receptor occupancy or signalling in the human brain are not available. Published reviews therefore present a plausible pathway rather than a confirmed sequence of events.
PT-141 was the internal development code assigned to bremelanotide during preclinical research. Reference sources sometimes index the peptide under the code rather than the generic name. The two terms describe the same molecule.